EWM
MRKR icon

Edge Wealth Management’s Marker Therapeutics MRKR Stock Holding History

Edge Wealth Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,350
Closed -$28K – 558
2020
Q2 		$28K Buy
1,350
+800
+145% +$17.5K 0.01% 320
2020
Q1 		$10K Sell
550
-250
-31% -$6.37K ﹤0.01% 399
2019
Q4 		$23K Sell
800
-1,400
-64% -$50.9K ﹤0.01% 325
2019
Q3 		$112K Buy
2,200
+2,000
+1,000% +$118K 0.03% 175
2019
Q2 		$15K Buy
+200
New +$11.9K ﹤0.01% 370

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Edge Wealth Management's MRKR Position: Q3 2020 in Review

Edge Wealth Management sold out of Marker Therapeutics (MRKR) in Q3 2020, closing a stake of 1,350 shares — an estimated $28K sold.

Edge Wealth Management first reported a position in MRKR in Q2 2019 and held it in 5 quarters. The position peaked at $112K in Q3 2019. 58 funds tracked by Wall St. Rank hold MRKR as of Q3 2020.

  • Edge Wealth Management reported no remaining Marker Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Edge Wealth Management sold 1,350 Marker Therapeutics shares in Q3 2020, an estimated $28K.
  • Edge Wealth Management first reported a position in Marker Therapeutics in Q2 2019 and held it in 5 quarters.
  • Edge Wealth Management's Marker Therapeutics position peaked at $112K in Q3 2019.
  • 58 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2020.

Based on Edge Wealth Management's 13F filing for Q3 2020, filed 21 Oct 2020.